Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Sep
26
2014
Nearly 10% of Americans Have Gone to Work High [INFOGRAPHIC] Risk and Insurance Management Society, Inc. (RIMS)
Sep
25
2014
Recent Settlement Highlights Importance of Tracing Country of Origin When Selling Medical Devices to the U.S. Government Covington & Burling LLP
Sep
25
2014
NFL and NFLPA Finalize Amended Substance Abuse Policies Jackson Lewis P.C.
Sep
24
2014
Mounting Legal Challenges to Florida Medical Marijuana Regulations Bilzin Sumberg
Sep
23
2014
FDA Proposes Revisions to the Proposed Foreign Supplier Verification Rule Covington & Burling LLP
Sep
23
2014
Energy & Environmental Law Update -- September 22, 2014 Mintz
Sep
23
2014
Biomarin Pharmaceutical Inc. v. Duke University: Authorizing Opposition to Motion to Exclude IPR2013-00535 Faegre Drinker
Sep
22
2014
Guilty Convictions in Salmonella Trial May Signify Landmark in Criminal Food-Safety Prosecutions Mintz
Sep
22
2014
FDA Issues Revisions to Proposed Food Safety Rules, Reopens Comment Period for Revisions Only Barnes & Thornburg LLP
Sep
22
2014
White House Mobilizes Forces Against Superbug Covington & Burling LLP
Sep
22
2014
Brazil: An Update of the Most Relevant Events for Pharmaceutical Companies in 2014: Part 1 of a 5-Part Series Michael Best & Friedrich LLP
Sep
22
2014
Major Damages Award in Pelvic Mesh Case Underscores the Critical Role of Internal Email in Jury Trials Covington & Burling LLP
Sep
20
2014
Court Rejects FDA’s Interpretation of the Statute’s Device Definition as “Erroneous and Unreasonable” Covington & Burling LLP
Sep
19
2014
DEA Controlled Substance Disposal Requirements Take Effect October 9, 2014 Beveridge & Diamond PC
Sep
19
2014
Internet/Social Media Platforms: FDA Draft Guidance Giordano, Halleran & Ciesla, P.C.
Sep
16
2014
President Obama’s Response to the Ebola Crisis Covington & Burling LLP
Sep
15
2014
340B Federal Drug Pricing Program September Update: Self-Disclosures McDermott Will & Emery
Sep
13
2014
Judge Requires PhRMA To Initiate New 340B Orphan Drug Lawsuit to Challenge Interpretive Rule Covington & Burling LLP
Sep
13
2014
Looking Towards the Future of Pharmaceuticals in Africa Covington & Burling LLP
Sep
12
2014
National Institute of Standards and Technology (NIST) Issues Draft Report Enumerating Risks and Protections to Consider When Evaluating Mobile Apps for Your Enterprise Mintz
Sep
11
2014
FutureGen Receives EPA Permits for Underground Injection Greenberg Traurig, LLP
Sep
11
2014
FDA Focuses on Sex-Specific Data in Medical Device Clinical Trials Covington & Burling LLP
Sep
11
2014
FDA Publishes “Purple Book” for Biologicals/Biosimilars
Sep
11
2014
Indefiniteness After The Supreme Court Nautilus Decision – A Very “Delicate Balance”
Sep
11
2014
Court of Federal Claims Stays Decision Requiring Commercial Item Contractor to Comply with Non-Commercial Practices Covington & Burling LLP
Sep
10
2014
Trouble Ahead For On-the-Job Post-Accident Drug Testing? Jackson Lewis P.C.
Sep
10
2014
Ariosa Diagnostics v. Isis Innovation Limited: Final Written Decision (Motion to Amend) IPR2012-00022 Faegre Drinker
Sep
9
2014
FTC Brings its First Post-Actavis Suit re: Pharmaceutical Patent Litigation Covington & Burling LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins